1,719 reports of this reaction
1.9% of all RISANKIZUMAB RZAA reports
#11 most reported adverse reaction
HEADACHE is the #11 most commonly reported adverse reaction for RISANKIZUMAB RZAA, manufactured by AbbVie Inc.. There are 1,719 FDA adverse event reports linking RISANKIZUMAB RZAA to HEADACHE. This represents approximately 1.9% of all 92,878 adverse event reports for this drug.
RISANKIZUMAB RZAA has an overall safety score of 78 out of 100. Patients taking RISANKIZUMAB RZAA who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is a less commonly reported adverse event for RISANKIZUMAB RZAA, but still significant enough to appear in the safety profile.
In addition to headache, the following adverse reactions have been reported for RISANKIZUMAB RZAA:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 1,719 FDA reports for RISANKIZUMAB RZAA. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 1.9% of all adverse event reports for RISANKIZUMAB RZAA, making it a notable side effect.
If you experience headache while taking RISANKIZUMAB RZAA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.